at Zacks.com (Jan 16, 2015)
Impax Labs (IPXL -11%) takes a hit on the back of the FDA's approval of Actavis' generic version of Shire's Adderall XR. Jefferies says the approval means an immediate hit to FY12 - 14 revenue and lowers its price target from $21 to $20.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 15, 2015)
at Zacks.com (Jan 13, 2015)
at Zacks.com (Jan 9, 2015)
at Benzinga.com (Jan 8, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs